Inhibitors of BCR and mTORC1 signaling cooperatively decreased the formation and function of the MYD88/TLR9/BCR supercomplex, providing mechanistic insight into their synergistic toxicity for MyD88/TLR9/BCR+ DLBCL cells [113]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.